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SUMMARY Azathioprine is a synthetic purine analog derived 
from 6-mercaptopurine. It is a purine antagonist and its active 
metabolites act by disrupting the function of endogenous purines. 
It has a cytotoxic and immunosuppressive mechanism of action. It 
is used in dermatology for treatment of immunobullous diseases, 
generalized eczematous disorders and photodermatoses. There 
is an enzyme in the metabolism of azathioprine called thiopurine 
s-methyltransferase (TPMT). It is very important to measure the 
TPMT activity before initiating therapy so that proper dosing of 
azathioprine can be achieved.
KEY WORDS: azathioprine, azathioprine use in dermatology, 
adverse effects of azathioprine
INTRODUCTION
 Dermatologists have been at the forefront of 
the application of azathioprine. It has been utilized 
in dermatology for several decades. Azathioprine 
is a synthetic purine analog derived from 6-mer-
captopurine (6-MP). It is thought to act by disrupt-
ing nucleic acid synthesis and has recently been 
found to interfere with T-cell activation. The most 
recognized uses of azathioprine in dermatology 
are for immunobullous diseases, generalized ec-
zematous disorders and photodermatoses.
In hopes of protecting 6-MP from metabolic deg-
radation, an imidazole ring was attached to the 
molecule and as a result, azathioprine (trade 
name, Imuran; GlaxoSmithKline) was created 
(1). Because of the favorable therapeutic index 
of azathioprine over other traditional immunosup-
pressants like 6-MP, methotrexate, 5-fluorouracil 
and actinomycin C (2), it has been utilized as a 
corticosteroid sparing agent and as monotherapy. 
The official US Food and Drug Administration indi-
cations are for prevention of rejection in renal ho-
motransplantation and for refractory, severe rheu-
matoid arthritis, yet physicians have successfully 
employed azathioprine to treat many conditions, 
including inflammatory bowel disease (Crohn’s 
disease and ulcerative colitis), multiple sclerosis, 
myasthenia gravis, malignancies and autoimmune 
conditions (3).
Azathioprine pharmacology
 All cells require nucleic acids for their growth. 
Knowing that, Hitchings and Elion postulated that 
synthetic purine analogs might halt growth of rap-
idly dividing cells (4). They wanted to increase the 
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efficiency of 6-MP by protecting it from rapid meta-
bolic catabolism. So, azathioprine was produced 
with the addition of an imidazole ring to the basic 
structure of 6-MP. Their intention was for azathio-
prine to be resistant to immediate catabolism and 
to be more selective in activation in target cells. In 
short period of time, the researches demonstrated 
that azathioprine was more active and had better 
therapeutic index than 6-MP did (1).
Pharmacokinetics and metabolism
 Azathioprine is quickly and almost completely 
absorbed from the digestive tract and does not 
cross the blood-brain barrier (5). It reaches the 
peak serum levels 2 hours after ingestion, and the 
half-life, including all active metabolites, is approxi-
mately 5 hours. Azathioprine is extensively metab-
olized, and only about 2% is excreted, unchanged, 
in the urine (6). There are two important enzymes 
in the metabolism of azathioprine. They are thio-
purine s-methyltransferase (TPMT) and xanthine 
oxidase (XO). They are important because as the 
result of their activity, the inactive metabolites are 
produced, and as the result of their decreased 
activity the toxic metabolites are produced. De-
creased TPMT activity is a consequence of ge-
netic polymorphisms, while decreased XO activity 
is frequently mediated by medications such as al-
lopurinol. The main active metabolites of azathio-
prine are 6-thioguanine nucleotides. 
Mechanism of action
 Azathioprine is a purine antagonist. The 6-thio-
guanine active metabolites of azathioprine disrupt 
the function of endogenous purines (7). So the 
generally accepted mechanism of azathioprine’s 
cytotoxic and immunosuppressive activities is dis-
ruption of nucleic acids and the interference with 
the activation of T cells. Because the nucleic acids 
are the building blocks of DNA, RNA and certain 
coenzymes, the synthesis of DNA, RNA and pro-
teins is disrupted (8).
Thiopurine methyltransferase
 Application of azathioprine to a patient with 
TPMT deficiency results in significant accumula-
tion of toxic metabolites, and it is clinically mani-
fested by increased hematopoietic toxicity, with 
potentially grave consequences (9).
 Testing for TPMT levels is helpful in the care of 
dermatologic patients in order to achieving proper 
dosing (10).
AZATHIOPRINE USE IN 
DERMATOLOGY
 Azathioprine has been used successfully to 
treat immunobullous diseases, precisely in pem-
phigus vulgaris for nearly 35 years, and has been 
accepted despite the lack of multiple perspec-
tive randomized, double-blinded controlled trials 
to support its use. It is used for treating eczema, 
actinic dermatitis and immunobullous diseases. 
Patients reported to have an excellent response 
are those who were able to eventually discontinue 
or reduce their corticosteroids to a very low dose 
(10 mg or less of prednisone equivalent) daily or a 
low dose (20 mg or less of prednisone equivalent) 
every day. Many patients were able to discontin-
ue completely their corticosteroids after several 
months of azathioprine treatment.
Immunobullous diseases
 Since1969, it has been successfully used for 
treating pemphigus vulgaris (11). Some clinicians 
also prefer it over other immunosuppressant med-
ications in the treatment of pemphigoid. It has also 
been used in treating cicatricial pemphigoid. 
Psoriasis and eczematous diseases
 It has been used in the treatment of psoriasis 
(12), eczema (atopic dermatitis, hand eczema, 
adult eczema) (12) and contact dermatitis. Inter-
est in azathioprine for treatment of psoriasis ap-
pears to have waned, but several recent publica-
tions have documented its successful use in adult 
and childhood eczema. Of all evidence supporting 
the use of azathioprine in dermatology, its use in 
eczematous diseases appears to be strongest. It 
also works extremely well to control generalized 
eczematous and pruritic conditions.
Photodermatoses
 Chronic actinic dermatitis is a group of disor-
ders aggravated by ultraviolet and visible light. 
It includes numerous photodermatoses such as 
photosensitive eczema, photosensitivity dermati-
tis, persistent light reaction, and actinic reticuloid. 
Strong evidence supports the use of azathioprine 
in the treatment of chronic actinic dermatitis (12). 
Some consider it the first choice for long-term im-
munosuppression of these conditions. It has also 
been reported to be helpful in severe polymor-
phous light eruption.
Other uses
 Azathioprine has also been used to treat Be-
hçet syndrome, pityriasis rubra pilaris, erythema 
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multiforme, lichen planus, vasculitis, cutaneous lu-
pus, Reiter syndrome, graft-versus-host disease, 
prurigo nodularis, Sulzberger and Garbe, and 
acne fulminans. It continues to be actively used in 
fields outside dermatology. Rheumatologists have 
employed it to treat systemic lupus erythematosus 
(SLE), scleroderma and dermatomyositis. It has 
also been utilized by gastroenterologists, neurolo-
gists and surgeons. 
Dosing
 Dermatologists have only recently begun 
checking TPMT activity before initiating therapy. 
Since TPMT was not measured in most prior stud-
ies, the lack of benefit may be accounted for by 
inadequate dosing-underdosing in patients with 
high TPMT activity (13).
PREGNANCY AND PEDIATRIC USE
Pregnancy considerations
 Azathioprine and 6-MP have been shown to 
cross human placenta in low concentrations and 
appear in fetal plasma after 24 hours. Although 
both drugs have been found in the placenta and 
amniotic fluid of patients taking azathioprine, the 
inactive metabolite thiouric acid has the greatest 
concentration (14). The immature liver lacks the 
enzyme necessary for conversion of 6-MP to the 
active metabolites, so the developing fetus likely 
has some protection from azathioprine toxicity 
early in pregnancy (14). Azathioprine’s teratoge-
nicity has not been conclusively established. It 
is tolerated fairly well in pregnancy, but the most 
commonly accepted concerns include infants born 
prematurely and infants small for gestational age. 
The rate of congenital malformations is dose-de-
pendent and varies from 3% to 9%. The malfor-
mations reported with azathioprine include micro-
cephaly, myelomeningocele, preaxial polydactyly, 
thymic atrophy, adrenal hypoplasia and hypospa-
dias. Hematologic abnormalities have also been 
reported, but it appears that maintaining the ma-
ternal leukocyte count within the normal limits may 
avert neonatal leukopenia and thrombocytopenia. 
Reports of infection have been minimal, but cy-
tomegalovirus and gram-negative infections have 
been reported. Azathioprine may in fact be unre-
lated to some of the reported anomalies, and alter-
natively, such defects may be due to the underly-
ing disease state instead. The general consensus 
is to reserve azathioprine for those pregnant pa-
tients with severe or life-threatening disease. Aza-
thioprine does not appear to affect fertility. Minimal 
concentrations of azathioprine and its metabolites 
have been found in breast milk. The hemoglo-
bin, leukocyte count, platelet count and growth 
rate were normal in a breast-fed infant of a pa-
tient on azathioprine. However, the potential risk 
of immune suppression and the theoretical risk of 
carcinogenesis outweigh the potential benefits of 
nursing according to the World Health Organiza-
tion (15).
Use in pediatric patients
 Azathioprine has been used successfully in pe-
diatric patients with immunobullous diseases, SLE 
and dermatomyositis. However, because of immu-
nosuppression concerns regarding the risk of in-
fection and potential development of malignancy, 
azathioprine should be reserved for those pediat-
ric patients in whom safer therapies have failed.
Drug interactions
 The most obvious interaction is with allopuri-
nol, an XO inhibitor used most often to treat gout. 
Since azathioprine is catabolized in part by XO, 
concomitant use may result in severe azathioprine 
toxicity and hematologic complications. Hemato-
logic complications appear to rise 4 to 6 weeks 
after combination therapy and reverse with its 
cessation. However, if both medications are ab-
solutely essential, one-quarter to one-third of the 
original azathioprine dose is recommended with 
close laboratory monitoring.
 Azathioprine has also been reported to induce 
warfarin resistance. There have been reports of 
patients on warfarin that bled severely after aza-
thioprine was discontinued. Recurrent thrombo-
sis with initiation of azathioprine therapy has also 
been reported. This interaction appears to be 
dose-dependent, so the warfarin dose may have 
to be increased 3 to 4 times to compensate for 
azathioprine’s interaction.
ADvERSE EffECTS
 Common side effects
 Azathioprine is generally well tolerated and has 
a favorable therapeutic index compared with many 
other traditional immunosuppressants. Patients 
overdosed on massive amounts of azathioprine 
were not left with any permanent impairment. The 
most common symptomatic side effects of azathi-
oprine are gastrointestinal, ranging from nausea, 
vomiting to diarrhea. These symptoms may re-
spond to dose adjustment (16), or taking the medi-
cation with food. However, azathioprine should be 
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immediately discontinued in those patients with 
severe gastrointestinal symptoms, as they may be 
developing an intolerant or hypersensitivity reac-
tion. Well-accepted concern with azathioprine is 
bone marrow depression, so laboratory monitor-
ing of complete blood count is important during the 
initial weeks of therapy.
 Dermatologic problems are more frequent in 
transplantation patients than in non-transplanta-
tion patients on azathioprine (17). Pale skin types, 
excess sun exposure and duration of allograft 
seem to be important risk factors in the develop-
ment of skin lesions. Common skin problems in-
clude alopecia, verrucae, zoster, increased skin 
color and malignant neoplasms.
Uncommon side effects
 Allergic contact dermatitis has been reported 
in persons who come into physical contact with 
azathioprine tablets. More severe systemic hy-
persensitivity reactions have been reported in 
patients taking azathioprine. This azathioprine 
intolerance or hypersensitivity reaction commonly 
occurs within the first 4 weeks of therapy. The find-
ings of hypersensitivity greatly vary and can range 
from fever, nausea, vomiting, diarrhea, arthralgia 
and malaise to hypotension, shock and possibly 
even death (18). Most of the cases are reported 
in patients with neurologic diseases, rheumato-
logic disorders and in transplantation patients. 
Hypersensitivity symptoms typically resolve in a 
few days (between 12 hours and 20 days) after 
discontinuation of azathioprine. 
Malignancy potential
 Skin type, sun exposure, dose and length of 
azathioprine treatment are important factors in de-
termining the risk of the development of skin can-
cer. Patients on higher doses and longer durations 
of azathioprine have been shown to be at an in-
creased risk of skin cancer, particularly squamous 
cell carcinoma. Aggressive squamous cell carci-
noma has been reported in dermatology patients 
with type 1 skin and greater than 4 years of azathi-
oprine therapy. Those with more immune suppres-
sion, such as heart transplantation patients, ap-
pear to be at a greater risk than those with lesser 
suppression, like kidney transplantation patients. 
Patients with psoriasis and dermatomyositis who 
have been undergoing azathioprine treatment for 
more than 5 years have been reported to develop 
non-Hodgkin lymphoma. Like skin cancer, internal 
malignancies such as lymphoma are increased in 
patients with higher doses and longer duration of 
immune suppression.
DOSING AND MONITORING
 A TPMT value should be obtained before start-
ing treatment, so the proper dose of azathioprine 
could be determined. Patients generally have re-
sponses after 150 mg/day in a few months of ther-
apy, and a trial should not be considered a failure 
unless the patient has been on an adequate dose 
for at least 3 months. The dose can be reduced on 
50 mg/kg. It is recommended to perform TPMT, 
pregnancy test, complete blood count and com-
plete metabolic panel at baseline. After initiation of 
therapy, complete blood cell count bimonthly and 
complete metabolic panel monthly for the first 2 
months of therapy, then monthly for a few months, 
and then every 3 months is suggested. Complete 
skin examination should be performed regularly if 
the patient has been on azathioprine for more than 
2 years.
CONCLUSION
 Azathioprine has been utilized for several de-
cades, yet only in a few studies TPMT levels were 
measured. It is possible that many patients found 
to be unresponsive to azathioprine were under-
dosed, and those determined to have significant 
hematologic toxicity had no or low TPMT activity.
 Azathioprine is an effective immunosuppres-
sant that is extremely valuable in treating pemphi-
gus vulgaris, pemphigoid, generalized eczematous 
disorders and actinic dermatitis, and will probably 
remain in dermatology for years to come.
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For winter sports - Nivea cream; year 1936.
(from the collection of Mr. Zlatko Puntijar)
